VA
VRCA icon

Verdad Advisers’s Verrica Pharmaceuticals VRCA Stock Holding History

Verdad Advisers’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$141K Buy
23,069
+10,971
+91% +$68.4K 0.14% 172
2026
Q1 		$64K Buy
+12,098
New +$77.5K 0.07% 168

Other funds holding VRCA

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $149M AUM 39.81% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Mariner
Mariner Overland Park, Kansas $95.2B AUM 32.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Verdad Advisers's VRCA Position: Q2 2026 in Review

Verdad Advisers increased its Verrica Pharmaceuticals (VRCA) stake by 91% in Q2 2026, buying an estimated $68.4K and bringing the position to 23,069 shares worth $141K. The position accounts for 0.14% of the portfolio, ranked #172.

Verdad Advisers first reported a position in VRCA in Q1 2026 and has held it in 2 quarters since. 43 funds tracked by Wall St. Rank hold VRCA as of Q2 2026.

  • Verdad Advisers held 23,069 shares of Verrica Pharmaceuticals worth $141K as of Q2 2026.
  • Verdad Advisers bought 10,971 Verrica Pharmaceuticals shares in Q2 2026, an estimated $68.4K.
  • Verrica Pharmaceuticals made up 0.14% of Verdad Advisers's portfolio in Q2 2026, its #172 holding.
  • Verdad Advisers first reported a position in Verrica Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 43 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q2 2026.

Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.